1. Early onset of efficacy with erenumab in patients with episodic and chronic migraine
- Author
-
Todd Schwedt, Uwe Reuter, Stewart Tepper, Messoud Ashina, David Kudrow, Gregor Broessner, Guy P. Boudreau, Peter McAllister, Thuy Vu, Feng Zhang, Sunfa Cheng, Hernan Picard, Shihua Wen, Joseph Kahn, Jan Klatt, and Daniel Mikol
- Subjects
Erenumab ,Chronic migraine ,Episodic migraine ,Efficacy ,Migraine preventive medication ,Onset of efficacy ,Medicine - Abstract
Abstract Background Subcutaneous erenumab reduced monthly migraine days and increased the likelihood of achieving a ≥ 50% reduction at all monthly assessment points tested in 2 pivotal trials in episodic migraine (EM) and chronic migraine (CM). Early efficacy of migraine preventive medications is an important treatment characteristic to patients. Delays in achievement of efficacy can result in failed adherence. The objective of these post-hoc analyses were to evaluate efficacy in the first 4 weeks after initial subcutaneous administration of erenumab 70 mg, erenumab 140 mg, or placebo. Methods There is no generally accepted methodology to measure onset of action for migraine preventive medications. We used a comprehensive approach with data from both studies to evaluate change from baseline in weekly migraine days (WMD), achievement of ≥ 50% reduction in WMD, and proportion of patients experiencing migraine measured on a daily basis. The 7-day moving averages were overlaid with observed data. Results In both studies (EM: N = 955; CM: N = 667), there was evidence of onset of efficacy of erenumab vs. placebo during the first week of treatment, which in some cases reached nominal significance. For EM the changes in WMD were (least squares mean [LSM] [95% CI]): placebo, − 0.1 (− 0.3, 0.0); erenumab 70 mg, − 0.3 (− 0.5, − 0.2) p = 0.130; erenumab 140 mg, − 0.6 (− 0.7, − 0.4) p
- Published
- 2018
- Full Text
- View/download PDF